2017 Buyer’s Guide

This buyer’s guide offers a searchable, comprehensive listing of the FDA-approved interventional devices available in the United States.

Postmarket Registry Evaluates B. Braun's Coroflex Isar Sirolimus-Eluting Stent

 

June 26, 2017—Findings from postmarket surveillance of the Coroflex Isar drug-coated stent (B. Braun Melsungen AG) for the treatment of real-world patients with de novo and restenotic lesions after stand-alone angioplasty in coronary arteries were published online by Florian Krackhardt, MD, et al in Open Heart.

B. Braun announced European CE Mark approval for Coroflex Isar in February 2014. The polymer-free matrix of Coroflex Isar consists of sirolimus and the matrix builder probucol that was initially studied in the Isar-Test 5 trial.

The Coroflex Isar 2000 Registry assessed the safety and efficacy of the ultrathin-strut Coroflex Isar polymer-free sirolimus-eluting stent (PF-SES) in an unselected patient population with a focus on acute coronary syndrome (ACS). In addition, the investigators studied stable coronary artery disease (CAD) with short (≤ 6 months) versus long (> 6 months) dual antiplatelet therapy (DAPT).

As summarized in Open Heart, this unselected large-scale international, multicenter, all-comers study evaluated patients who received the PF-SES. The primary endpoint was the 9-month target lesion revascularization (TLR) rate. Secondary endpoints included the 9-month major adverse cardiac events (MACE) and procedural success rates. The investigators evaluated subgroups defined a priori, such as patients with ACS, diabetes, lesion subsets, and procedural characteristics relative to DAPT.

The investigators reported that a total of 2,877 patients, of whom 1,084 had ACS, were treated with PF-SES (1.31 ± 0.75 stents per patient). At 9 months, the accumulated overall TLR rate was 2.3% (58/2513). There was no significant difference between ACS and stable CAD (2.6% vs 2.1%; P = .389). The overall MACE rate was 4.3% (108/2513) with a higher rate in patients with ACS when compared with the stable CAD subgroup (6.1% [58/947] vs 3.2% [50/1566]; P < .001).

The study demonstrated that PF-SES angioplasty is safe and effective in daily clinical routine with low rates of TLR and MACE in an unselected patient population. The data are in agreement with previous clinical findings that an extended DAPT duration beyond 6 months does not improve clinical outcomes in patients with stable CAD, stated the investigators in Open Heart.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.